Influenza, Human: all 2,264 studies

Page 7 of 23. Open to participants first (173), then studies with results posted, then the rest; newest registration first within each.

• Immunogenicity and Safety of a Single 0.5 mL Dose of Inflexal V With a 0.25 mL 2-dose Regimen of Inflexal VCompletedNCT01229397Phase 3Results posted
• Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two SuppliersCompletedNCT01229371Phase 3Results posted
• Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for ComplicationsCompletedNCT01227967Phase 2Results posted
• Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated InfluenzaCompletedNCT01227421Phase 2/3Results posted
• A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or OlderCompletedNCT01222403Phase 4Results posted
• Study of Quadrivalent Influenza Vaccine Among AdultsCompletedNCT01218646Phase 3Results posted
• A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in ChildrenCompletedNCT01218308Phase 3Results posted
• Influenza Vaccine Post Allogeneic TransplantTerminatedNCT01215981Not applicableResults posted
• Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of AgeCompletedNCT01209780Phase 3Results posted
• Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIVCompletedNCT01205581Phase 2Results posted
• Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A)CompletedNCT01204671Phase 3Results posted
• Relenza® Sentinel Site Monitoring Program in JapanCompletedNCT01199744Results posted
• A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in ChildrenCompletedNCT01198756Phase 3Results posted
• Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in ChildrenCompletedNCT01196988Phase 3Results posted
• A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in AdultsCompletedNCT01196975Phase 3Results posted
• Immunogenicity and Safety Study of Fluarix™ Vaccine in Children Who Have Previously Been Vaccinated With Pandemrix™CompletedNCT01196026Phase 4Results posted
• Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy ChildrenTerminatedNCT01195779Phase 2Results posted
• Study of Live, Attenuated Influenza Vaccination in Preterm and Full-Term InfantsTerminatedNCT01194297Phase 4Results posted
• Immunogenicity and Safety Study of FluarixTM Vaccine in Children Who Have Previously Been Vaccinated With PandemrixTMCompletedNCT01190215Phase 4Results posted
• Cell Mediated Immunity in Older AdultsCompletedNCT01189123Not applicableResults posted
• Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding WomenCompletedNCT01181323Phase 2Results posted
• 2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant WomenCompletedNCT01173211Phase 2Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster DoseCompletedNCT01171989Phase 2Results posted
• Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly SubjectsCompletedNCT01162122Phase 3Results posted
• Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in Children 3 to Less Than 10 Years OldCompletedNCT01161160Phase 2Results posted
• Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TMTerminatedNCT01160237Phase 3Results posted
• Prophylactic Efficacy of Relenza Against Influenza A and BCompletedNCT01156701Results posted
• Immunogenicity & Safety Study of Fluviral® (2010 - 2011 Season) in Adults Aged 18 to 60 Years and Over 60 YearsCompletedNCT01153685Phase 3Results posted
• Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2010-2011CompletedNCT01152814Phase 2Results posted
• Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy AdultsCompletedNCT01147068Phase 1/2Results posted
• TextFluenza: Using Technology To Promote Flu Vaccination In Underserved Maternal And Child PopulationsCompletedNCT01146912Not applicableResults posted
• A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in AdultsCompletedNCT01144299Phase 3Results posted
• Study of GSK Biologicals' Influenza Vaccine Arepanrix™ in Japanese Adults 65 Years of Age or OlderCompletedNCT01114620Phase 4Results posted
• Trial to Evaluate the Safety and the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Healthy ChildrenCompletedNCT01096056Phase 1Results posted
• Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated InfluenzaCompletedNCT01068912Phase 2Results posted
• Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in AdultsCompletedNCT01059617Phase 1Results posted
• Study of Nitazoxanide in Adults With Acute Uncomplicated InfluenzaTerminatedNCT01056380Phase 2Results posted
• Effects of Age on Response to the 2009 H1N1 Virus VaccineCompletedNCT01055184Phase 1/2Results posted
• A Study of Intravenous Oseltamivir [Tamiflu] in Infants With InfluenzaTerminatedNCT01053663Phase 1Results posted
• Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating InfluenzaCompletedNCT01052480Phase 2Results posted
• Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of AgeCompletedNCT01051661Phase 3Results posted
• A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With InfluenzaCompletedNCT01050257Phase 3Results posted
• Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children Aged 10 to Less Than 18 YearsCompletedNCT01035749Phase 2Results posted
• A Study of Intravenous Tamiflu (Oseltamivir) in Children With InfluenzaCompletedNCT01033734Phase 1Results posted
• A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu StrainTerminatedNCT01032837Phase 4Results posted
• Infectivity, Replication & Immunogenicity of Live nH1N1 VaccineCompletedNCT01023776Phase 4Results posted
• Immunologic Response to Inactivated Vaccine for Novel H1N1 VirusCompletedNCT01023711Not applicableResults posted
• Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in HospitalCompletedNCT01014988Phase 2Results posted
• Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in ChildrenTerminatedNCT01014091Phase 3Results posted
• Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IMCompletedNCT01011049Phase 2Results posted
• The Effect of Fact Versus Myth Messages on Receipt of Influenza VaccinationCompletedNCT01009645Not applicableResults posted
• Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in ChildrenTerminatedNCT01003418Phase 2Results posted
• Does Seasonal Influenza Vaccination Affect the Incidence of pH1N1 Influenza?CompletedNCT01001325Phase 3Results posted
• Safety and Immunogenocity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Japanese ChildrenCompletedNCT01001169Phase 2Results posted
• Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 MonthsCompletedNCT00996307Phase 2/3Results posted
• Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal VaccinesCompletedNCT00993668Phase 4Results posted
• Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and YouthCompletedNCT00992836Phase 2Results posted
• Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly PeopleCompletedNCT00992784Phase 3Results posted
• Novartis H1N1 Vaccine in Pregnant WomenCompletedNCT00992719Phase 2Results posted
• Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults, Using Two Different Manufacturing ProcessesCompletedNCT00992511Phase 3Results posted
• H1N1 Vaccine at Two Dose Levels in HIV Positive AdultsCompletedNCT00992433Phase 2Results posted
• Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant WomenCompletedNCT00992017Phase 2Results posted
• Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1)CompletedNCT00989612Phase 2Results posted
• Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in AdultsCompletedNCT00989287Phase 3Results posted
• A Pharmacokinetic/Pharmacodynamic (PK/PD) and Safety Evaluation of Oseltamivir [Tamiflu] in the Treatment of Infants 0 to <12 Months of Age With Confirmed Flu InfectionCompletedNCT00988325Phase 1Results posted
• A Study of Influenza Virus Vaccines in Children and AdultsCompletedNCT00988143Phase 2Results posted
• Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine in Healthy ChildrenCompletedNCT00985790Phase 2Results posted
• Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in AdultsCompletedNCT00985673Phase 2Results posted
• Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and OlderCompletedNCT00985088Phase 2Results posted
• Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in ChildrenCompletedNCT00980005Phase 3Results posted
• Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and OlderCompletedNCT00979602Phase 3Results posted
• Study to Evaluate Immunological Equivalence Between Two Investigational Influenza Vaccines in Adults (H1N1)CompletedNCT00979407Phase 3Results posted
• Safety and Efficacy of an H1N1 Influenza Vaccine in People With AsthmaCompletedNCT00978120Phase 2Results posted
• Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of AgeCompletedNCT00976820Phase 2Results posted
• Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and OlderTerminatedNCT00976027Phase 3Results posted
• Study to Evaluate Immunogenicity & Safety of an Investigational Influenza Vaccine in AdultsCompletedNCT00975884Phase 3Results posted
• Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)CompletedNCT00973700Phase 3Results posted
• Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly AdultsCompletedNCT00973349Phase 2/3Results posted
• Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years)CompletedNCT00972816Phase 2/3Results posted
• Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in ChildrenCompletedNCT00972517Phase 3Results posted
• Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)CompletedNCT00971425Phase 3Results posted
• Safety, Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)CompletedNCT00971321Phase 2Results posted
• STIP: Statin Trial for Influenza PatientsTerminatedNCT00970606Not applicableResults posted
• Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of AgeCompletedNCT00970307Phase 2Results posted
• Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Fluarix™ Vaccine When Co-administered in ElderlyCompletedNCT00968890Phase 2Results posted
• Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in AdultsCompletedNCT00968539Phase 3Results posted
• Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in AdultsCompletedNCT00968526Phase 3Results posted
• Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults >= 65 Years of AgeCompletedNCT00966238Phase 2Results posted
• Mechanisms of Severe Acute Influenza Consortium (MOSAIC)CompletedNCT00965354Results posted
• Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)CompletedNCT00964158Phase 3Results posted
• H1N1 Vaccine in Pregnant WomenCompletedNCT00963430Phase 2Results posted
• Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly PopulationsCompletedNCT00963157Phase 2Results posted
• A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric PopulationCompletedNCT00959049Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to InfluenzaTerminatedNCT00958776Phase 3Results posted
• A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USACompletedNCT00958243Phase 2Results posted
• A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USACompletedNCT00958126Phase 2Results posted
• Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected InfluenzaCompletedNCT00957996Phase 3Results posted
• Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010CompletedNCT00956761Phase 2Results posted
• A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the ElderlyCompletedNCT00953524Phase 2Results posted
• A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 YearsCompletedNCT00952419Phase 2Results posted

← Influenza, Human overview